<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675844</url>
  </required_header>
  <id_info>
    <org_study_id>ACH443-904</org_study_id>
    <nct_id>NCT00675844</nct_id>
  </id_info>
  <brief_title>An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment</brief_title>
  <official_title>An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48-Weeks in Subjects Who Have Completed 96 -Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bellos, Nicholaos C., M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Texas Primary Care Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orlando Immunology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Michael</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for the Prevention and Treatment of Infections</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extension study for subjects currently participating in protocols ACH443-015 and ACH443-018.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1-infected, clinically stable, treatment-na√Øve adults who have completed 96-weeks of
      elvucitabine therapy in protocol ACH443-015 and whose HIV RNA levels remain below 50
      copies/mL from the 92-week assessment in protocol ACH443-015 or subjects who have completed
      48-weeks of elvucitabine therapy in protocol ACH443-018 and continue to maintain a HIV-1 RNA
      viral load below their baseline level upon entry into protocol ACH443-018
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety profile of elvucitabine as measured by the incidence of study discontinuations and the incidence, severity and type of AEs and clinically significant changes or abnormalities in the subject's clinical laboratory results.</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the continued efficacy of elvucitabine as measured by the change in helper T cell (CD4) count.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>elvucitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects currently receiving elvucitabine will continue elvucitabine as part of their ART regimen for an additional 48 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elvucitabine</intervention_name>
    <description>10 mg elvucitabine daily as part of an ART regimen</description>
    <arm_group_label>elvucitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have successfully completed 96 weeks of elvucitabine therapy in Protocol
             ACH443-015 OR subjects have completed 48-weeks of elvucitabine therapy in protocol
             ACH443-014A / 018.

        Exclusion Criteria:

          -  Subject has experienced viroligic rebound as defined in section 5.6.1.3 of protocol
             ACH443-015.

          -  Subject has exceeded their baseline HIV-1 RNA level by Week 44 as measured in protocol
             ACH443-014A / 018

          -  Subject is experiencing a drug-related Grade 3 or 4 rash or a drug related grade 3 or
             4 laboratory toxicity other than Grade 3 or 4 cholesterol, triglyceride,creatinine
             kinase, or LDH.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Olek, DO</last_name>
    <role>Study Director</role>
    <affiliation>Achillion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for the Prevention and Treatment of Infections</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicholaos Bellos, MD</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <disposition_first_submitted>January 20, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 20, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 13, 2014</disposition_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <name_title>Ronald Gugliotti, MPH</name_title>
    <organization>Achillion Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Extension study</keyword>
  <keyword>HIV-1 infection</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zalcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

